Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05542264 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT05542264 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 19 participants.
The verdict
NCT05542264, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters. This study is accepting male and female participants age 18 years to 65 years. This study will be conducted in approximately 6 study sites in the United States. Participation could last up to 13 weeks.
Interventions
- DRUG SEP-363856
- DRUG Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2024-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05542264
The ClinicalTrials.gov registry entry for NCT05542264 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SEP-363856 is the first listed.
NCT05542264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05542264 about?
NCT05542264 is a clinical study titled "A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia". A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters. This study is accepting male and female participants age 18 years to 65 years. This study will be co...
What is the current status of trial NCT05542264?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2022-11-15. Estimated completion is 2024-02-12.
What interventions are being tested in trial NCT05542264?
The interventions under investigation include: SEP-363856 (DRUG), Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) (DRUG).
Who is sponsoring clinical trial NCT05542264?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.